JP7109427B2 - ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 - Google Patents

ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 Download PDF

Info

Publication number
JP7109427B2
JP7109427B2 JP2019515776A JP2019515776A JP7109427B2 JP 7109427 B2 JP7109427 B2 JP 7109427B2 JP 2019515776 A JP2019515776 A JP 2019515776A JP 2019515776 A JP2019515776 A JP 2019515776A JP 7109427 B2 JP7109427 B2 JP 7109427B2
Authority
JP
Japan
Prior art keywords
composition
asparaginase
polyalkylene oxide
subject
sodium phosphate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019515776A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019521179A (ja
JP2019521179A5 (enExample
Inventor
フォルナシニ，ジャンフランコ
スークアレヴァ，ナデジダ
フィリップス，クリストファー
Original Assignee
セルヴィエ アイピー ユーケー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60992770&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7109427(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by セルヴィエ アイピー ユーケー リミテッド filed Critical セルヴィエ アイピー ユーケー リミテッド
Publication of JP2019521179A publication Critical patent/JP2019521179A/ja
Publication of JP2019521179A5 publication Critical patent/JP2019521179A5/ja
Priority to JP2022030538A priority Critical patent/JP7857767B2/ja
Application granted granted Critical
Publication of JP7109427B2 publication Critical patent/JP7109427B2/ja
Priority to JP2025181444A priority patent/JP2026016612A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/50—Hydrolases (3) acting on carbon-nitrogen bonds, other than peptide bonds (3.5), e.g. asparaginase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/542—Carboxylic acids, e.g. a fatty acid or an amino acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6921—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a particulate, a powder, an adsorbate, a bead or a sphere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/78—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5)
    • C12N9/80—Hydrolases (3) acting on carbon to nitrogen bonds other than peptide bonds (3.5) acting on amide bonds in linear amides (3.5.1)
    • C12N9/82—Asparaginase (3.5.1.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y305/00—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5)
    • C12Y305/01—Hydrolases acting on carbon-nitrogen bonds, other than peptide bonds (3.5) in linear amides (3.5.1)
    • C12Y305/01001—Asparaginase (3.5.1.1)
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019515776A 2016-06-01 2017-06-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法 Active JP7109427B2 (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2022030538A JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201662344252P 2016-06-01 2016-06-01
US201662344249P 2016-06-01 2016-06-01
US201662344256P 2016-06-01 2016-06-01
US62/344,252 2016-06-01
US62/344,249 2016-06-01
US62/344,256 2016-06-01
PCT/US2017/035461 WO2018017190A2 (en) 2016-06-01 2017-06-01 Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022030538A Division JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Publications (3)

Publication Number Publication Date
JP2019521179A JP2019521179A (ja) 2019-07-25
JP2019521179A5 JP2019521179A5 (enExample) 2020-06-18
JP7109427B2 true JP7109427B2 (ja) 2022-07-29

Family

ID=60992770

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019515776A Active JP7109427B2 (ja) 2016-06-01 2017-06-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2022030538A Active JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A Pending JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2022030538A Active JP7857767B2 (ja) 2016-06-01 2022-03-01 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP2025181444A Pending JP2026016612A (ja) 2016-06-01 2025-10-28 ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法

Country Status (32)

Country Link
US (3) US12343387B2 (enExample)
EP (3) EP4778589A2 (enExample)
JP (3) JP7109427B2 (enExample)
KR (3) KR102783452B1 (enExample)
CN (1) CN109640961B (enExample)
AU (1) AU2017299374B2 (enExample)
BR (1) BR112018074823B1 (enExample)
CA (1) CA3026070A1 (enExample)
CL (1) CL2018003418A1 (enExample)
CO (1) CO2018013753A2 (enExample)
CY (1) CY1124980T1 (enExample)
DK (1) DK3463308T4 (enExample)
ES (1) ES2905874T5 (enExample)
FI (1) FI3463308T4 (enExample)
HR (1) HRP20212027T4 (enExample)
HU (1) HUE057856T2 (enExample)
IL (2) IL312621A (enExample)
LT (1) LT3463308T (enExample)
MX (2) MX388814B (enExample)
MY (1) MY198474A (enExample)
PH (1) PH12018502540A1 (enExample)
PL (1) PL3463308T5 (enExample)
PT (1) PT3463308T (enExample)
RS (1) RS62979B2 (enExample)
RU (1) RU2758796C2 (enExample)
SA (1) SA518400557B1 (enExample)
SG (1) SG11201810685WA (enExample)
SI (1) SI3463308T2 (enExample)
SM (1) SMT202200049T1 (enExample)
UA (1) UA123020C2 (enExample)
WO (1) WO2018017190A2 (enExample)
ZA (2) ZA201807943B (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018150196A1 (en) 2017-02-17 2018-08-23 Oxford University Innovation Limited Cell penetrating peptides modified by glycosylation
GB201812972D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
GB201812980D0 (en) 2018-08-09 2018-09-26 Univ Oxford Innovation Ltd Cell-penetrating peptides
WO2020089743A1 (en) 2018-11-02 2020-05-07 Cadila Healthcare Limited Pharmaceutical composition of pegylated l-asparaginase
AU2019394177A1 (en) 2018-12-07 2021-06-10 Oxford University Innovation Limited Linkers
EA202191646A1 (ru) * 2018-12-24 2022-01-14 Дженнова Биофармасьютикалз Лимитед Лиофилизированная композиция пегаспаргазы
CA3211038A1 (en) 2021-02-12 2022-08-18 Oxford University Innovation Limited Cell-penetrating peptide conjugates and methods of their use
KR20230165799A (ko) * 2021-04-06 2023-12-05 재즈 파마슈티칼즈 아일랜드 리미티드 L-아스파라기나제의 제제
CN114392237B (zh) * 2021-12-28 2024-02-02 上海允英生物医药科技有限公司 一种冻干病毒制剂及其制备方法
CN119326875A (zh) * 2024-12-23 2025-01-21 中国人民解放军总医院第三医学中心 L-ASNase在制备治疗膀胱癌药物中的应用及试剂盒

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520764A (ja) 1999-02-22 2003-07-08 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
JP2005528351A (ja) 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
JP2006517600A (ja) 2003-01-06 2006-07-27 ネクター セラピューティクス アラバマ，コーポレイション チオール選択的水溶性ポリマー誘導体
US20100143324A1 (en) 2007-06-08 2010-06-10 Oy Reagena Ltd. Method for treatment of cancers or inflammatory diseases
CN102138909B (zh) 2010-12-30 2013-03-13 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液
JP2013538788A (ja) 2010-06-25 2013-10-17 シャイアー ヒューマン ジェネティック セラピーズ， インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物

Family Cites Families (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2433883C2 (de) * 1973-07-20 1986-03-27 Research Corp., New York, N.Y. Verwendung von physiologisch aktiven Polypeptiden
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
DE3279834D1 (en) * 1981-12-31 1989-08-31 Asta Pharma Ag 4-sulfido-oxaza phosphorines and their use in the treatment of cancer, and in immunosuppression
JPS58183626A (ja) 1982-04-21 1983-10-26 Nippon Oil Co Ltd 白血病治療用ｌ−アスパラギナ−ゼ固定化剤
US4729957A (en) 1984-12-13 1988-03-08 The United States Of America As Represented By The Department Of Health And Human Services Process for manufacture of L-asparaginase from erwinia chrysanthemi
US5324844A (en) 1989-04-19 1994-06-28 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
US5122614A (en) 1989-04-19 1992-06-16 Enzon, Inc. Active carbonates of polyalkylene oxides for modification of polypeptides
ATE300519T1 (de) * 1989-04-19 2005-08-15 Enzon Inc Verfahren zum herstellen von modifizierten polypeptiden die eine polypeptid und ein polyalkylenoxid enthalten
GB9017002D0 (en) 1990-08-02 1990-09-19 Health Lab Service Board Improved method for the purification of erwina l-asparaginase
US5618710A (en) * 1990-08-03 1997-04-08 Vertex Pharmaceuticals, Inc. Crosslinked enzyme crystals
TW197439B (enExample) 1991-04-04 1993-01-01 Ueno Pharmaceutics Applic Res Co Ltd
US5283253A (en) 1991-09-23 1994-02-01 Florida State University Furyl or thienyl carbonyl substituted taxanes and pharmaceutical compositions containing them
WO1993010076A1 (en) 1991-11-22 1993-05-27 The University Of Mississippi Synthesis and optical resolution of the taxol side chain and related compounds
US5200534A (en) 1992-03-13 1993-04-06 University Of Florida Process for the preparation of taxol and 10-deacetyltaxol
AU4242993A (en) 1992-05-21 1993-12-13 Penn State Research Foundation, The Cultured (taxus) tissues as a source of taxol, related taxanes and other novel anti-tumor/anti-viral compounds
US5274137A (en) 1992-06-23 1993-12-28 Nicolaou K C Intermediates for preparation of taxols
US5294637A (en) 1992-07-01 1994-03-15 Bristol-Myers Squibb Company Fluoro taxols
US5202448A (en) 1992-08-14 1993-04-13 Napro Biotherapeutics, Inc. Processes of converting taxanes into baccatin III
CA2100808A1 (en) 1992-10-01 1994-04-02 Vittorio Farina Deoxy paclitaxels
FR2696463B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696464B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveau procédé d'estérification de la baccatine III et de la désacétyl-10 baccatine III.
FR2696462B1 (fr) 1992-10-05 1994-11-25 Rhone Poulenc Rorer Sa Procédé d'obtention de la désacétyl-10 baccatine III.
FR2696458B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Procédé de préparation de dérivés du taxane.
FR2696461B1 (fr) 1992-10-05 1994-11-10 Rhone Poulenc Rorer Sa Nouveaux dérivés d'analogues du taxol, leur préparation et les compositions qui les contiennent.
US5279949A (en) 1992-12-07 1994-01-18 Board Of Trustees Operating Michigan State University Process for the isolation and purification of taxol and taxanes from Taxus spp
US6277828B1 (en) 1993-08-20 2001-08-21 Syntex (U.S.A.) Inc. Pharmaceutical formulations of nerve growth factor
US5824701A (en) 1993-10-20 1998-10-20 Enzon, Inc. Taxane-based prodrugs
US5415869A (en) 1993-11-12 1995-05-16 The Research Foundation Of State University Of New York Taxol formulation
US5599902A (en) 1994-11-10 1997-02-04 Arizona Board Of Regents Acting On Behalf Of Arizona State University Cancer inhibitory peptides
US6087151A (en) 1995-02-08 2000-07-11 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo DNA coding for mammalian L-asparaginase
EP0831100B1 (en) 1995-04-21 2000-10-11 Teikoku Hormone Mfg. Co., Ltd. Novel peptide derivatives
CA2226575C (en) 1995-07-27 2011-10-18 Genentech, Inc. Stabile isotonic lyophilized protein formulation
US6537547B1 (en) 1996-06-07 2003-03-25 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Polypeptides having L-asparaginase activity
WO1998008833A1 (en) 1996-08-26 1998-03-05 Bristol-Myers Squibb Company Sulfenamide taxane derivatives
AU739028B2 (en) 1996-09-27 2001-10-04 Bristol-Myers Squibb Company Hydrolyzable prodrugs for delivery of anticancer drugs to metastatic cells
WO1998022451A1 (en) 1996-11-19 1998-05-28 Daiichi Pharmaceutical Co., Ltd. Taxol derivatives
US5977386A (en) 1996-12-24 1999-11-02 Bristol-Myers Squibb Company 6-thio-substituted paclitaxels
ZA983497B (en) 1997-04-28 1999-10-25 Lilly Co Eli Activated protein c formulations.
EP0988050B1 (en) 1997-06-09 2004-04-28 Childrens Hospital Of Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
US6991788B1 (en) 1997-06-09 2006-01-31 Childrens Hospital Los Angeles Utilization of wolinella succinogenes asparaginase to treat diseases associated with asparagine dependence
IL133585A0 (en) 1997-06-20 2001-04-30 Baker Norton Pharma Soluble prodrugs of paclitaxel
US7288665B1 (en) 1997-08-18 2007-10-30 Florida State University Process for selective derivatization of taxanes
US5854051A (en) 1997-09-15 1998-12-29 Heska Corporation Parasitic helminth asparaginase proteins, nucleic acid molecules, and uses thereof
JPH1192468A (ja) 1997-09-17 1999-04-06 Yakult Honsha Co Ltd 新規なタキサン誘導体
WO1999018113A1 (fr) 1997-10-08 1999-04-15 Bio Research Corporation Of Yokohama Derives taxoides et leur procede de production
US6180095B1 (en) 1997-12-17 2001-01-30 Enzon, Inc. Polymeric prodrugs of amino- and hydroxyl-containing bioactive agents
CA2324467C (en) 1998-03-26 2002-11-05 Schering Corporation Formulations for protection of peg-interferon alpha conjugates
US6323315B1 (en) 1999-09-10 2001-11-27 Basf Aktiengesellschaft Dolastatin peptides
US20020065397A1 (en) 2000-10-12 2002-05-30 Joseph Roberts Protecting therapeutic compositions from host-mediated inactivation
EP1391213A1 (en) 2002-08-21 2004-02-25 Boehringer Ingelheim International GmbH Compositions and methods for treating cancer using maytansinoid CD44 antibody immunoconjugates and chemotherapeutic agents
CN101484181B (zh) 2006-06-30 2012-12-26 希格马托罕见疾病公司 用于生产l-天门冬酰胺酶ⅱ的重组宿主
US20080260820A1 (en) * 2007-04-19 2008-10-23 Gilles Borrelly Oral dosage formulations of protease-resistant polypeptides
AU2008240796A1 (en) 2007-04-20 2008-10-30 Dsm Ip Assets B.V. Asparaginase enzyme variants and uses thereof
WO2011003633A1 (en) 2009-07-06 2011-01-13 Alize Pharma Ii Pegylated l-asparaginase
US9322008B2 (en) 2010-09-01 2016-04-26 Indian Institute Of Technology Mutants of L-asparaginase
RU2441914C1 (ru) 2010-10-06 2012-02-10 Учреждение Российской академии медицинских наук Научно-исследовательский институт биомедицинской химии имени В.Н. Ореховича РАМН (ИБМХ РАМН) Способ получения субстанции рекомбинантной l-аспарагиназы erwinia carotovora
US9051561B2 (en) 2011-10-10 2015-06-09 Children's Hospital Los Angeles Asparaginase and treating diseases associated with asparagine dependence
CN102657852A (zh) * 2012-05-22 2012-09-12 范铭琦 重组沃氏菌天门冬酰胺酶药物组合物及其制备法和应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003520764A (ja) 1999-02-22 2003-07-08 バクスター・インターナショナル・インコーポレイテッド 新規のアルブミンを含有していない第ｖｉｉｉ因子処方物
JP2005528351A (ja) 2002-03-08 2005-09-22 イーライ・リリー・アンド・カンパニー 活性化プロテインｃ製剤
JP2006517600A (ja) 2003-01-06 2006-07-27 ネクター セラピューティクス アラバマ，コーポレイション チオール選択的水溶性ポリマー誘導体
US20100143324A1 (en) 2007-06-08 2010-06-10 Oy Reagena Ltd. Method for treatment of cancers or inflammatory diseases
JP2013538788A (ja) 2010-06-25 2013-10-17 シャイアー ヒューマン ジェネティック セラピーズ， インコーポレイテッド アリールスルファターゼａのｃｎｓ送達の方法および組成物
CN102138909B (zh) 2010-12-30 2013-03-13 常州千红生化制药股份有限公司 门冬酰胺酶冻干粉针剂及其制备方法以及门冬酰胺酶溶解液

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
International Journal of Pharmaceutics，1999年，Vol.187，pp.153-162
International Journal of Pharmaceutics，2002年，Vol.237，pp.163-170

Also Published As

Publication number Publication date
JP2019521179A (ja) 2019-07-25
CN109640961A (zh) 2019-04-16
LT3463308T (lt) 2022-02-10
KR20220165820A (ko) 2022-12-15
WO2018017190A2 (en) 2018-01-25
PL3463308T3 (pl) 2022-03-14
UA123020C2 (uk) 2021-02-03
CO2018013753A2 (es) 2019-01-18
SG11201810685WA (en) 2018-12-28
JP7857767B2 (ja) 2026-05-13
RU2018146395A (ru) 2020-07-09
EP4778589A2 (en) 2026-07-22
MX388814B (es) 2025-03-20
BR112018074823A2 (pt) 2019-03-06
EP3463308B1 (en) 2021-12-01
RS62979B1 (sr) 2022-03-31
IL263349A (en) 2019-01-31
AU2017299374B2 (en) 2021-05-27
IL263349B2 (en) 2024-10-01
PL3463308T5 (pl) 2026-04-07
EP3463308A2 (en) 2019-04-10
JP2026016612A (ja) 2026-02-03
KR20190015366A (ko) 2019-02-13
MX2018014916A (es) 2019-07-18
KR102783452B1 (ko) 2025-03-19
WO2018017190A3 (en) 2018-03-01
CY1124980T1 (el) 2023-01-05
MX2021015544A (es) 2022-02-23
HRP20212027T1 (hr) 2022-04-01
CN109640961B (zh) 2021-11-02
BR112018074823B1 (pt) 2024-02-27
PT3463308T (pt) 2022-03-11
US20240108701A1 (en) 2024-04-04
KR102473887B1 (ko) 2022-12-06
CA3026070A1 (en) 2018-01-25
MY198474A (en) 2023-08-31
RU2758796C2 (ru) 2021-11-01
RS62979B2 (sr) 2026-03-31
US12343387B2 (en) 2025-07-01
ZA201807943B (en) 2022-09-28
SMT202200049T1 (it) 2022-03-21
DK3463308T4 (da) 2026-02-09
US20190240300A1 (en) 2019-08-08
NZ788906A (en) 2025-07-25
DK3463308T3 (da) 2022-01-31
EP4019007A1 (en) 2022-06-29
JP2022071060A (ja) 2022-05-13
IL312621A (en) 2024-07-01
NZ749069A (en) 2025-02-28
AU2017299374A1 (en) 2018-12-20
EP3463308B2 (en) 2026-01-07
FI3463308T4 (fi) 2026-03-12
ES2905874T3 (es) 2022-04-12
HRP20212027T4 (hr) 2026-02-13
CL2018003418A1 (es) 2019-05-24
PH12018502540A1 (en) 2019-04-08
US20250242004A1 (en) 2025-07-31
ZA202202259B (en) 2022-11-30
SA518400557B1 (ar) 2024-02-29
SI3463308T2 (sl) 2026-03-31
KR20230162139A (ko) 2023-11-28
SI3463308T1 (sl) 2022-04-29
RU2018146395A3 (enExample) 2020-07-09
IL263349B1 (en) 2024-06-01
ES2905874T5 (en) 2026-05-14
EP3463308A4 (en) 2019-12-18
HUE057856T2 (hu) 2022-06-28

Similar Documents

Publication Publication Date Title
JP7857767B2 (ja) ポリアルキレンオキシド－アスパラギナーゼの製剤ならびにその製造法および使用法
JP4785816B2 (ja) 抗新生物薬剤、特にテモゾロミドの薬学的処方物、その同一物の製造方法および使用方法
CN113365613A (zh) 透明质酸和表没食子儿茶素-3-o-没食子酸酯的缀合物和纳米颗粒及其用途
Weng et al. Application of microneedles combined with dendritic cell-targeted nanovaccine delivery system in percutaneous immunotherapy for triple-negative breast cancer
HK40076514A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HK40006539A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HK40006539B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
HK40007007B (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same
EA040430B1 (ru) Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение
EA052831B1 (ru) Препараты полиалкиленоксид-аспарагиназы и способы их получения и применение
HK40007007A (en) Formulations of polyalkylene oxide-asparaginase and methods of making and using the same

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200508

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200508

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210317

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210324

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210624

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210727

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20211108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220301

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20220301

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20220310

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20220426

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20220427

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220609

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220616

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220627

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220719

R150 Certificate of patent or registration of utility model

Ref document number: 7109427

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250